The news this morning couldn’t have been worse for Endocyte Inc. But if it had to come, the timing couldn’t have been better–because it allowed Endocyte to raise a pile of cash to spend on the other drugs in its pipeline.
Endocyte Inc.’s stock fell more than 60 percent in early trading Friday after the drug it’s developing with Merck & Co.’s backing failed to help patients in a trial for ovarian cancer.
The envisioned 26-acre, $200-million-or-more complex would bridge IU’s School of Medicine with the city’s life sciences firms, including those at the nascent 16 Tech, a business park.
A new report from the Commonwealth Fund provides plenty to criticize everyone involved in health care in Indiana: It shows health care costs run higher in Indiana than the rest of the country while patients’ health and the quality of health care providers in some key areas are worse.
Until doctors and hospitals make a whole lot more headway—or, perhaps, more accurately, are allowed to make more headway—in offering package deals, it’s hard to see major progress on containing out-of-control health care costs.
Indianapolis Business Journal gathered leaders in Indiana’s life sciences industry for a Power Breakfast panel discussion April 24. Among other topics, the panelists discussed whether Obamacare helps or hurts companies in the industry, the biggest barrier to life sciences startups, and how rising activity among angel investors has changed the life sciences landscape.
The typical hospital around the country will see its profits wiped out entirely by the changes coming from health reform and the aging of the population. But in Indianapolis, the hits will be cushioned by this region's fatter commercial reimbursements.
The deal will help Zimmer, a maker of artificial hips and knees, take on Johnson & Johnson, the No. 1 manufacturer in the now-growing $45 billion market.
The Indianapolis-based subsidiary of the country’s largest chemical maker achieved all-time highs in revenue and earnings in the first quarter.
Eli Lilly and Co. has agreed to pay $5.4 billion for Novartis Animal Health in the second-largest deal in the company's history. The acquisition is part of a blockbuster three-way drug deal.
The Indianapolis-based pharmaceutical maker gets a much-needed boost with FDA approval for gastric-cancer drug ramucirumab, which quickly could account for $1 billion in annual sales.
Indiana is the most profitable state for Indianapolis-based WellPoint Inc., which operates Blue Cross and Blue Shield health plans in 14 states. WellPoint’s margin for Indiana in 2012 was 5.8 percent, 38 percent higher than WellPoint’s national average.
WellPoint’s commanding market share gave it a whopping $129 million in profit from its risk-based insurance products in 2012. But in percentage terms, WellPoint was not at the top of the heap.
For consumers that get tax subsidies in the Obamacare exchanges, out-of-pocket premiums will remain steady even if insurers raise prices next year. But the subsidies could fall if insurers offer lower-cost plans.
From this week’s historic data dump, I learned who the top 20 recipients of Medicare payments are in Indianapolis (hint: mostly labs, ambulances and eye surgeons). But the real takeaway is that meaningful price information about doctors is still a long way away.
Court win last week in a patent challenge to lung cancer drug Alimta pushed Lilly shares higher than they’ve ever been since April 2007. Since then, the company’s pipeline has produced more misfires than the villains in a James Bond movie
Another public stock offering by the West Lafayette-based drugmaker swells its war chest for cancer drug development to $225 million.
The scramble for physicians by hospitals in recent years has led to more than a dozen physicians cracking a million dollars in compensation—and three dozen receiving at least a half million dollars. Hospitals, meanwhile, are recording big losses on their physician practices.
For now, at least, the year-to-year price increases of individual insurance under Obamacare look a lot like they did before Obamacare. That’s not a failure, but it’s not a success either.
